FASN and prostate carcinoma: Regulates lipid and cholesterol production by inhibiting sterol regulatory element binding proteins (SREBP)1 and 2. Downregulates fatty acid synthase (FASN) and 3hydroxy3methylglutaryl CoA reductase (HMGCR) in prostate cancer cell lines, inhibiting cell growth, migration, and invasion.